Abstract: A fusion bead testing device is provided for testing the strength of a fusion bead removed from a pipe joint. The testing device comprises a first pressing means for exerting a force against the fusion bead. If the fusion bead splits as a result of the applied force then the fusion bead fails a quality control test and the fusion bead and consequently the pipe joint from which the bead was removed are deemed too weak. The fusion bead testing apparatus comprises an automatic split detection device for detecting a split in the bead.

Abstract: A fusion bead testing device is provided for testing the strength of a fusion bead removed from a pipe joint. The testing device comprises a first pressing means for exerting a force against the fusion bead. If the fusion bead splits as a result of the applied force then the fusion bead fails a quality control test and the fusion bead and consequently the pipe joint from which the bead was removed are deemed too weak. The fusion bead testing apparatus comprises an automatic split detection device for detecting a split in the bead.

Abstract: The present invention provides humanised antibodies and binding domains thereof with anti-tumor activity. In particular the humanised antibodies have specific binding to and direct killing of human colon tumor cells and display potent immune-mediated cytotoxic activity against human colon cancer cells in vitro using antibody-dependent cell-mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) assays and in vivo using mouse tumor models.

Abstract: A fusion bead testing device is provided for testing the strength of a fusion bead removed from a pipe joint. The testing device comprises a first pressing means for exerting a force against the fusion bead. If the fusion bead splits as a result of the applied force then the fusion bead fails a quality control test and the fusion bead and consequently the pipe joint from which the bead was removed are deemed too weak. The fusion bead testing apparatus comprises an automatic split detection device for detecting a split in the bead.

Abstract: The present invention provides humanised antibodies and binding domains thereof with anti-tumour activity. In particular the humanised antibodies have specific binding to and direct killing of human colon tumour cells and display potent immune-mediated cytotoxic activity against human colon cancer cells in vitro using antibody-dependent cell-mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) assays and in vivo using mouse tumour models.

Abstract: The present invention provides humanized antibodies and binding domains thereof with anti-tumor activity. In particular the humanized antibodies have specific binding to and direct killing of human colon tumor cells and display potent immune-mediated cytotoxic activity against human colon cancer cells in vitro using antibody-dependent cell-mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) assays and in vivo using mouse tumor models.

Abstract: Previously a number of techniques have been used in order to form single crystal or pre-determined crystallography components and articles. Each one of these techniques has its own particular problems, including susceptibility to error. By utilization of a bi-crystal experiment to determine melt-back length LM and by consideration of the ingress distance d from potential initiation nucleation points on a perimeter of a seed crystal, it is possible to determine a maximum ingress length d. By ensuring that the maximum ingress length d is less than or equal to a seed crystal diameter R, it is possible to project locus from potential nucleation points C1, C2 in terms of potential radii for stray grain propagation. As the seed crystal will have a known crystalline orientation, it will be possible to consider two divergent growth curves of the crystal in terms of the stray grains propagating from the point C1, C2.

Abstract: The present invention provides a recombinant domain antibody (dAb) which binds to human TNF-?, the dAb comprising an immunoglobulin heavy or light chain variable domain, comprising at least one complementarity determining region (CDR) having a sequence derived from a New World primate.

Abstract: The present invention provides a recombinant domain antibody (dAb) which binds to human TNF?, the dAb comprising an immunoglobulin heavy or light chain variable domain comprising at least one complementarity determining region (CDR) having a sequence derived from a New World primate.

Abstract: The present invention provides an antibody comprising an antigen binding domain which binds to human IL-12 and human IL-23. The antibody binds human IL-12p40 existing as a monomer (human IL-12p40) and as a homodimer (human IL-12p80) and the antibody inhibits the binding of human IL-12 to human IL-12R ?2 and human IL-23 to human IL-23R but does not inhibit the binding of human IL-12 or human IL-23 or human IL-12p40 or human IL-12p80 to human IL-12R?1.

Abstract: The present invention provides a recombinant domain antibody (dAb) which binds to human TNF-?, the dAb comprising an immunoglobulin heavy or light chain variable domain, wherein said variable domain comprises at least one complementarity determining region (CDR) having a sequence derived from a New World primate.

Abstract: The present invention provides a recombinant domain antibody (dAb) which binds to human TNF-?, the dAb comprising an immunoglobulin heavy or light chain variable domain, wherein the variable domain comprises at least one complementarity determining region (CDR) having a sequence derived from a New World primate.

Abstract: The present invention provides a domain antibody construct which binds to human TNF-?, with the construct comprising: (a) a domain antibody (dAb) which binds to human TNF-?; (b) a modified hinge region sequence; (c) a human or primate heavy chain constant region sequence having a truncated CH1 domain of not more than 20 residues, wherein the modified hinge region sequence contains either a deletion or a single amino acid substitution of at least one cysteine residue which normally facilitates disulfide bond formation between heavy and light antibody chains.

Abstract: The present invention provides a domain antibody construct which binds to human TNF-?, with the construct comprising: (a) a domain antibody (dAb) which binds to human TNF-?; (b) a modified hinge region sequence; (c) a human or primate heavy chain constant region sequence having a truncated CH1 domain of not more than 20 residues, wherein the modified hinge region sequence contains either a deletion or a single amino acid substitution of at least one cysteine residue which normally facilitates disulfide bond formation between heavy and light antibody chains.

Abstract: The present invention provides humanised antibodies and binding domains thereof with anti-tumour activity. In particular the humanised antibodies have specific binding to and direct killing of human colon tumour cells and display potent immune-mediated cytotoxic activity against human colon cancer cells in vitro using antibody-dependent cell-mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) assays and in vivo using mouse tumour models.

Abstract: The present invention provides a chimeric antibody polypeptide comprising an antigen binding site, wherein the antigen binding site comprises a human variable domain having at least one New World Primate CDR.

Abstract: The present invention provides a recombinant domain antibody (dAb) which binds to human TNF-?, the dAb comprising an immunoglobulin heavy or light chain variable domain, wherein said variable domain comprises at least one complementarity determining region (CDR) having a sequence derived from a New World primate.

Abstract: Previously a number of techniques have been used in order to form single crystal or pre-determined crystallography components and articles. Each one of these techniques has its own particular problems, including susceptibility to error. By utilisation of a bi-crystal experiment to determine melt-back length LM and by consideration of the ingress distance d from potential initiation nucleation points on a perimeter of a seed crystal, it is possible to determine a maximum ingress length d. By ensuring that the maximum ingress length d is less than or equal to a seed crystal diameter R, it is possible to project locus from potential nucleation points C1, C2 in terms of potential radii for stray grain propagation. As the seed crystal will have a known crystalline orientation, it will be possible to consider two divergent growth curves of the crystal in terms of the stray grains propagating from the point C1, C2.

Abstract: Previously a number of techniques have been used in order to form single crystal or pre-determined crystallography components and articles. Each one of these techniques has its own particular problems, including susceptibility to error. By utilisation of a bi-crystal experiment to determine melt-back length LM and by consideration of the ingress distance d from potential initiation nucleation points on a perimeter of a seed crystal, it is possible to determine a maximum ingress length d. By ensuring that the maximum ingress length d is less than or equal to a seed crystal diameter R, it is possible to project locus from potential nucleation points C1, C2 in terms of potential radii for stray grain propagation. As the seed crystal will have a known crystalline orientation, it will be possible to consider two divergent growth curves of the crystal in terms of the stray grains propagating from the point C1, C2.

Abstract: The present invention provides a chimeric antibody or an antigen-binding portion thereof.